Pharmaceutical Executive-02-01-2021

Looking back at 1982-1985.

Almost a year since the start of the pandemic, it’s clear a new medical vision is taking shape—one focused on serving patients now, solving procedural issues later.

Melissa Thompson, Alcon’s head of global corporate social responsibility, discusses her career commitment to CSR and how COVID-19 has impacted the organization’s efforts to improve access to eye care around the globe.

Pharma manufacturers may need to upgrade their coupon programs to accommodate for the emergence of copay accumulators and related benefit mechanisms.

A look at the results of recent surveys revealing the impact of the COVID-triggered digital switchover on sales rep interactions and medical conferences.

Dueling paths leave market fortunes uncertain.

Can private sector serve public interests in battling rare diseases?

With the UK maintaining a world-leading position in key areas of technology, 2021 could be a banner year for its life sciences.

COVID-19 creates a unique chance to refocus STEM strategies.

Creating stronger relationships can set off a chain of success.

Click the title above for a link to open the Pharmaceutical Executive February 2021 issue in an interactive PDF format.

Panelists in a recent roundtable share ideas on transforming company culture, fostering greater patient diversity, and acting on pharma’s fast-evolving social mandate.

Not to be outdone by the showbiz industry, Pharm Exec's own awards season is fast approaching.

Telemedicine is definitely here to stay, but recent study may offer clues on its sustaining power.

Applications put on hold as agency limits alternative oversight methods.